An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy.

Szablewski, Vanessa; Bret, Caroline; Kassambara, Alboukadel; Devin, Julie; Cartron, Guillaume; Costes-Martineau, Valérie; Moreaux, Jérôme

Szablewski, Vanessa; Bret, Caroline; Kassambara, Alboukadel; Devin, Julie; Cartron, Guillaume; Costes-Martineau, Valérie; Moreaux, Jérôme.

Afiliación

Szablewski V; University of Montpellier, UFR de Médecine, Montpellier, France.
Bret C; Department of Biopathology, CHU Montpellier, Montpellier, France.
Kassambara A; Department of Biological Hematology, CHU Montpellier, Montpellier, France.
Devin J; Institute of Human Genetics, CNRS-UM UMR 9002, Montpellier, France.
Cartron G; University of Montpellier, UFR de Médecine, Montpellier, France.
Costes-Martineau V; Department of Biological Hematology, CHU Montpellier, Montpellier, France.
Moreaux J; Institute of Human Genetics, CNRS-UM UMR 9002, Montpellier, France.

Oncotarget ; 9(27): 19079-19099, 2018 Apr 10.

Article en En | MEDLINE | ID: mdl-29721185

Palabras clave

Diffuse large B cells lymphoma; epigenetics; gene expression profiling; prognostic value; targeted treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Francia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google